Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16785292 | 0.80 | PTPN5 (0.41) | DEGS1ALDH1A1ESR1ESR2CYP2D6 | |
| SCHEMBL15961450 | 0.78 | CYP2A6 (0.40) | CYP2A6CYP1A2ALOX5PYCR1ALDH1A1 | |
| SCHEMBL13852045 | 0.78 | IDO1 (0.39) | DEGS1CTSLALDH1A1ESR1ESR2 | |
| SCHEMBL10194742 | 0.78 | IDO1 (0.39) | DEGS1CTSLALDH1A1ESR1ESR2 | |
| SCHEMBL15961481 | 0.78 | CYP2A6 (0.40) | CYP2A6CYP1A2ALOX5PYCR1ALDH1A1 | |
| SCHEMBL12602992 | 0.78 | CHRNA7 (0.41) | ALOX5DEGS1CTSLCTSBCTSS | |
| SCHEMBL2600036 | 0.78 | CYP2A6 (0.40) | CYP2A6CYP1A2ALOX5PYCR1ALDH1A1 | |
| SCHEMBL7899070 | 0.76 | ESR1 (0.62) | CYP1A2DEGS1ALDH1A1ESR1ESR2 | |
| SCHEMBL13852046 | 0.76 | ADRB2 (0.50) | CYP2A6DEGS1ESR1ESR2HPGD | |
| SCHEMBL2678110 | 0.76 | MEN1 (0.38) | DEGS1ALDH1A1ESR1ESR2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111362833-A | Dianthracene D-delta-A type deep blue organic fluorescent material and preparation method and application thereof | 陕西师范大学 | 2020-07-03 | — | — | CN | claimed |
| US-12435054-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4185386-B1 | HETEROCYCLIC INHIBITORS OF TEAD FOR TREATING CANCER | GENENTECH INC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11787775-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787775-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787775-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4185386-A1 | HETEROCYCLIC INHIBITORS OF TEAD FOR TREATING CANCER | Genentech, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-111362833-B | Double anthracene D-delta-A type deep blue organic fluorescent material and preparation method and application thereof | 陕西师范大学 | 2023-04-25 | — | — | CN | disclosed |
| US-20230054741-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230054741-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| CN-111362833-A | Dianthracene D-delta-A type deep blue organic fluorescent material and preparation method and application thereof | 陕西师范大学 | 2020-07-03 | — | — | CN | disclosed |
| US-9856275-B2 | Synthesis and use of fluorinated compounds | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160002270-A1 | SYNTHESIS AND USE OF FLUORINATED COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-07 | — | — | US | disclosed |
| WO-2014035872-A1 | TRICYCLIC ALKYNES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014035872-A1 | TRICYCLIC ALKYNES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002270-A1 | SYNTHESIS AND USE OF FLUORINATED COMPOUNDS | AFF2, AFF4, AFF1 | CYP2A6 141/4885CYP1A2 47/4885ALOX5 800/4885 |
| US-20230054741-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, NQO1, PCSK9 | CYP2A6 1302/4885CYP1A2 1372/4885ALOX5 316/4885 |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, NQO1, PCSK9 | CYP2A6 1302/4885CYP1A2 1372/4885ALOX5 316/4885 |
| US-11787775-B2 | Therapeutic compounds and methods of use | VHL, NQO1, PCSK9 | CYP2A6 1302/4885CYP1A2 1372/4885ALOX5 316/4885 |
| US-12435054-B2 | Therapeutic compounds and methods of use | VHL, NQO1, PCSK9 | CYP2A6 1302/4885CYP1A2 1372/4885ALOX5 316/4885 |
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | CYP2A6 1183/4885CYP1A2 612/4885ALOX5 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.